Multiple Headlands Research Sites Selected for AstraZeneca’s Phase 3 COVID-19 Vaccine Trial

Headlands Research recently announced its research centers have been selected to participate in AstraZeneca’s upcoming Phase 3 COVID-19 vaccine trial. Headlands has built an industry-leading position in the vaccine and infectious disease space, successfully conducting over 250 vaccine, prophylaxis, and treatment trials to date across its North American sites.

Recruitment efforts for the AstraZeneca vaccine are actively underway at four of Headlands’ research sites, including Atlanta, GA; McAllen, TX; Lake Charles, LA; and Palm Beach, FL. Headlands employs a diversity of traditional and non-traditional recruiting sources for its COVID-19 vaccine and treatment trials, with a strong focus on ensuring the inclusion of a wide array of ethnic and age groups.

“A vaccine for COVID-19 is crucial to overcome the current pandemic, and we appreciate the opportunity to work with AstraZeneca on this important Phase 3 trial,” said Mark Blumling, CEO of Headlands Research.

Headlands Research was founded on the belief that clinical trial research needs to significantly evolve to better match the current healthcare climate, as well as the real-world needs of patients. Its mission is to profoundly change the clinical process by integrating novel technologies into a platform of best-in-class research facilities that gather high-quality data through increased trial participation while addressing specialty populations that are underserved. Based in San Francisco and backed by leading global investment firm KKR, Headlands aims to ensure that high-quality therapeutics are made available to patients who can benefit from them. For more information, visit